Rong WU, MD

Research Assistant Professor
Department of Pathology
University of Michigan
Medical School
Ann Arbor, MI, USA

Biography

Dr. Wu earned her Medical Degree and MS from Qingdao Medical College, PR, China in 1982 and 1986. She completed her Postdoctoral Fellowship in the Department of Pathology at Johns Hopkins University in 1998 and in the Department of Pathology in the University of Michigan in 2000. She was a Visiting Scientist in the Department of Pathology at the University of Cambridge (England) in 1992-1993. She became Research Investigator in the Department of Pathology in the University of Michigan Medical School in 2002 and Research Assistant Professor in 2009. She has a lengthy track record of research in the biology and genetics of gynecological cancers. Over the last twenty years, she has extensive experience in the development of genetically engineered mouse models for studying ovarian cancers.

Research Interest

Her research interests include: Molecular and genetic pathogenesis of gynecological tumors, especially ovarian carcinomas, Mouse models of human cancers.

Scientific Activities

HONORS AND AWARDS

• Sino-British Friendship Scholarship Award, sponsored by the Chinese government and British Council, Beijing, PR, China and London, UK, (1991)
• Outstanding Faculty Award, Qingdao Medical College, Qingdao, PR, China, (1994 and 1995)
• Scientific and Technologic Award, Education Committee, Shandong Province, Jinan, PR, China, (1995 and 1996)
• 100 Promising Young Investigators Award in Shandong Province, Education Committee, Shandong Province, Jinan, PR, China, (1996)
• Scholarship Award, China Scholarship Council, Beijing, PR, China, (1996)
• Fellowship/Travel Scholarship, the 6th Annual Workshop on the Pathology of Mouse Models for Human Disease. The Jackson Laboratory, Bar Harbor, ME, (2007)

PROFESSIONAL MEMBERSHIPS

• (4/1997-Present) Member of The Johns Hopkins Medical and Surgical Association
• (1/2000-Present) Active member of American Association for Cancer Research

Publications

PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Yutian Y, Baolin L, Xiangrui J, Wu R, Liou T. Cytomegalovirus (CMV) infection in cases of infantile autopsies. Chinese Journal of Pathology (Chinese). 1986; 15(2): 128-129.
2. Meihuai Y, Wu R. Mikuliczs disease with tumor-like hyperplasia of lymphoid tissue. Acta Academiae Medicinae Qingdao (Chinese). 1986; 22(1): 63-65.
3. Yutian Z, Wu R, Xiangrui J. Cytomegalovirus infection in infantile autopsies. Chinese Medical Journal. 1987; 100(9): 753-755.
4. Wu R. The immunohistochemical study of carcinoembryonic antigen in uterine carcinoma. Journal of Clinical and Experimental Pathology (Chinese). 1987; 3(4): 218-221.
5. Wu R, Jianche J, Jie S. The cyst formation in the duodenum after gastrectomy. Acta Academiae Medicinae Qingdao (Chinese). 1989; 25(4): 299
6. Wu R, Min Z, Xianlu S. The significance of CEA detection in serum and tissue of patients with gastrointestinal carcinoma. Acta Academiae Medicinae Qingdao (Chinese). 1990; 26(3): 227-230.
7. Bohua C, Wu R, Yunwen Z, et al. Experimental study of removal of sublaminar wires after spinal fixation. Chinese Journal of Surgery (Chinese). 1990; 28(7): 433-435.
8. Wu R. A study of nucleolar organizer regions in cystadenomatous neoplasm of the ovary. Acta Academiae Medicinae Qingdao (Chinese). 1991; 27(1): 50-52.
9. Wu R, Yutian Z, Xiangrui J, Cheng G, Aifeng L. Chlamydia trachomatis detection in tissues of human spontaneous abortion. Journal of Clinical and Experimental Pathology (Chinese). 1992; 8: 38-39.
10. Chen B, Hu Y, Zhou B, Wu R. Melanoma in the spinal cords. Chinese Journal of Neurosurgery (Chinese). 1993; 9(2): 65-67.
11. Wu R. The effect of tumor necrosis factor on the sensitivity of cervical carcinoma in cytotoxicity. Acta Academiae Medicinae Qingdao (Chinese). 1994; 30(3): 185-188.
12. Wu R, Coleman N, Stanley MA. The significance of IFN gamma in cytotoxicity mediated by lymphocytes to cervical keratinocytes. Chinese Journal of Microbiology and Immunology (Chinese). 1994; 14(4): 253-256.
13. Wu R, Coleman N, Stanley M. The expression of tumor necrosis factor in cervical cell lines and tissues by in situ hybridization. Chinese Journal of Obstetrics and Gynecology (Chinese). 1995; 30(11): 693-694.
14. Xiangrui J, Wu R, Xiumei Z, et al. The detection and clinical analysis of Chlamydia trachomatis infection in female genital tract. Chinese Journal of Obstetrics and Gynecology (Chinese). 1995; 30(9): 561-562.
15. Wu R, Wencui Z, Min Z, Shouyi D, Yuzhen J, Shuxian X. Detection of human papillomavirus DNA by in situ hybridization. Acta Academiae Medicinae Qingdao (Chinese). 1996; 32(3): 192-193.
16. Wu R, Coleman N, Stanley M. Differential susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity. Chinese Medical Journal. 1996; 109(11): 854-858.
17. Wu R, Stanley M, Shouyi D. The study of cytotoxicity mediated by tumor necrosis factor to cervical carcinoma derived cell lines in vitro. Journal of QiLu oncology (Chinese). 1997; 4(3): 170-172.
18. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research. 1997; 57(18): 3935-3940.
19. Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Research. 1997; 57(22): 4692-4698.
20. Wu R, Xiangrui J, Shouyi D, Zhimin W, Min Z. Expression of tumor necrosis factor mRNA, protein and receptor protein products in cervical neoplasm. Chinese Medical Journal. 1998; 111(11): 1046-1047.
21. Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett B. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. American Journal of Pathology. 1999; 154(6): 1849-1855. doi: 10.1016/S0002-9440(10)65442-9
22. Wu R, Connolly D, Ren X, Fearon ER, Cho KR. Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian cancers. Neoplasia. 1999; 1(4): 311-314.
23. Wu R, Connolly D, Cho KR. Restored expression of Fragile Histidine Triad protein and tumorigenicity of cervical carcinoma cells. Journal of the National Cancer Institute. 2000; 92(4): 338-344. doi: 10.1093/jnci/92.4.338
24. Connolly D, Greenspan D, Wu R, et al. Loss of Fhit protein expression in invasive cervical carcinoma and intraepithelial lesions associated with invasive disease. Clinical Cancer Research. 2000; 6(9): 3505-3510.
25. Wu R, Connolly D, Ngelangel C, Bosch FX, Muñoz N, Cho KR. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene. 2000; 19(48): 5543-5546.
26. Wu R, Zhai Y, Fearon ER, and Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Research. 2001; 61(22): 8247-8255.
27. Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell. 2002; 1(2): 145-155.
28. Leung JY, Kolligs FT, Wu R, et al. Activation of AXIN2 expression by beta-catenin/TCF: A feedback repressor pathway regulating Wnt signaling. Journal of Biological Chemistry. 2002; 277(24): 21657-21665. doi: 10.1074/jbc.M200139200
29. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Research. 2002; 62(16): 4722-472.
30. Lin L, Miller CT, Contreras JI, et al. The hepatocyte nuclear factor 3 gene, HNF3 (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Research. 2002; 62(18): 5273-5279.
31. Zhai Y, Wu R, Schwartz DR, et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. American Journal of Pathology. 2002; 160(4): 1229-1238.
32. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Research. 2003; 63(11): 2913-2922.
33. Wu R, Lin L, Beer DG, Ellenson LH, et al. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. American Journal of Pathology. 2003; 162(5): 1603-1610. doi: 10.1016/S0002-9440(10)64294-0
34. Shedden KA, Kshirsagar MP, Schwartz DR, et al. Histologic type, organ of origin, and wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clinical Cancer Research. 2005; 11(6): 2123-2131. doi: 10.1158/1078-0432.CCR-04-2061
35. Wang YF, Wu R, Cho KR, Shedden KA, Barder TJ, Lubman DM. Classification of cancer cell lines using an automated 2-D liquid mapping method with hierarchical clustering techniques. Molecular and Cellular Proteomics. 2006; 5(1): 43-52.
36. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Research. 2006; 66(3): 1354-1362. doi: 10.1158/0008-5472.CAN-05-3694
37. Zhu Y, Wu R, Sangha N, et al. Classifications of ovarian cancer tissues by proteomic patterns. Proteomics. 2006; 6(21): 5846-5956. doi: 10.1002/pmic.200600165
38. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007; 11(4): 321-333. doi: 10.1016/j.ccr.2007.02.016
39. Kim H, Wu R, Cho KR, et al. Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas. Proteomics-Clinical Applications. 2008; 2(4): 571-584. doi: 10.1002/prca.200780004
40. Sangha N, Wu R, Kuick R, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008; 10(12): 1362-1372.
41. Wang Y, Wu R, Cho KR, et al. Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. J Proteome Res. 2009; 3: 1452-1463.
42. Bommer GT, Feng Y, Iura A, et al. IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem. 2010; 285(3): 1928-1938. doi: 10.1074/jbc.M109.060319.
43. Zhai Y, Iura A, Yeasmin S, et al. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma. Oncogene. 2011; 30(40): 4152-4162. doi: 10.1038/onc.2011.123
44. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res. 2011; 17(23): 7359-7372. doi: 10.1158/1078-0432.CCR-11-1388.
45. Hu PJ, Knoepp SM, Wu R, Cho KR. Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis. Genes Chromosomes Cancer. 2012; 51(3): 283-289. doi: 10.1002/gcc.20953
46. Bian C, Wu R, Cho K, Yu X. Loss of BRCA1-A complex function in RAP80 null tumor cells. PLoS One. 2012; 7(7): e40406. doi: 10.1371/journal.pone.0040406
47. Wang H, Galbán S, Wu R, et al. Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res. 2013; 19(1): 158-169. doi: 10.1158/1078-0432.CCR-12-2380
48. Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol. 2013; 182(4): 1391-1399. doi: 10.1016/j.ajpath.2012.12.031